<ul>
<li>剩餘的 540 萬美元債務通過戰略性股權轉換為普通股償還，沒有附加的認股權證或調整條款</li>
<li>公司預計截至 12 月 31 日的資產負債表將不再反映任何未償還的可轉換債務</li>
<li>無債務的資產負債表為 2026 年的加速增長奠定了基礎，預計將有潛在的藥物批准和診所擴展</li>
</ul>
<p>特拉華州威爾明頓，2025 年 12 月 18 日（GLOBE NEWSWIRE）-- NRx Pharmaceuticals, Inc.（納斯達克：NRXP），一家臨牀階段生物製藥公司，今天宣佈已通過普通股的股權轉換向 Anson Funds, LLC 償還了剩餘的 540 萬美元資產負債表債務。此交易沒有附帶認股權證或其他重新定價機制。Anson 最初向公司借款 1620 萬美元，用於償還之前的貸款和公司運營費用。通過此次償還，公司預計在 2025 年日曆年結束時將實現無債務的資產負債表。NRx 認為這一里程碑為公司的資本結構適當定位，以便在未來一年實現加速增長，預計將有藥物批准和診所擴展。</p>
<p>“我們感謝 Anson Funds 在生物技術股票面臨挑戰的時期對我們公司的支持，並使我們能夠推進我們的製藥和臨牀項目，以期在 2026 年獲得批准並擴展，以支持有自殺傾向的抑鬱症和創傷後應激障礙患者，” NRx Pharmaceuticals 及其子公司 HOPE Therapeutics 的董事長兼首席執行官 Jonathan Javitt 博士表示。</p>
<p><strong>關於 NRx Pharmaceuticals, Inc.</strong></p>
<p>NRx Pharmaceuticals, Inc.（www.nrxpharma.com）是一家臨牀階段生物製藥公司，開發基於其 NMDA 平台的治療藥物，針對中樞神經系統疾病，特別是自殺性抑鬱症、慢性疼痛和創傷後應激障礙。公司正在開發 NRX-100（無防腐劑的靜脈注射氯胺酮）和 NRX-101（口服 D-氨基酸/氟哌啶醇）。NRX-100 已獲得針對抑鬱症中自殺意念的快速通道認證，包括雙相抑鬱症。NRX-101 已獲得針對自殺性雙相抑鬱症的突破性療法認證。NRx 最近重新提交了簡化新藥申請（ANDA），並啓動了 NRX-100 的新藥申請，申請用於治療抑鬱症患者的自殺意念，包括雙相抑鬱症的國家優先券計劃。</p>
<p><strong>關於前瞻性聲明的通知</strong></p>
<p>此處包含的信息包括根據 1934 年證券交易法第 21E 條及 1933 年證券法第 27A 條的修訂版的前瞻性聲明。前瞻性聲明通常包括預測性質的陳述，依賴於或涉及未來事件或條件，幷包括諸如 “可能”、“將”、“應該”、“會”、“期望”、“計劃”、“相信”、“打算”、“期待” 等類似表達。這些陳述涉及未來事件或公司的未來財務表現，並涉及已知和未知的風險、不確定性及其他因素，這些因素可能導致公司的實際結果與這些前瞻性聲明所表達或暗示的任何未來結果、活動水平、表現或成就存在重大差異。公司已報告已實現的監管里程碑，但未預測任何未來監管決定的結果。您不應對前瞻性聲明過於依賴，因為它們涉及已知和未知的風險、不確定性及其他因素，這些因素在某些情況下超出了公司的控制範圍，並可能會對實際結果、活動水平、表現或成就產生重大影響。任何前瞻性聲明反映了公司對未來事件的當前看法，並受這些及其他風險的影響，包括與公司運營、運營結果、增長戰略及其他事項（包括流動性）相關的不確定性和假設。有關公司及可能影響前瞻性聲明實現的風險因素的更詳細信息已在公司最近的 10-K 表格年度報告及其他向證券交易委員會提交的文件中列出。投資者和證券持有人被敦促在 SEC 網站上免費閲讀這些文件，網址為 <strong>http://www.sec.gov</strong>。除非適用法律要求，否則公司不承擔公開更新或修訂這些前瞻性聲明的義務，或更新實際結果可能與這些前瞻性聲明中預期的結果存在重大差異的原因，無論是由於新信息、未來事件還是其他原因。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>如需更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td><strong><em>Matthew Duffy</em></strong> NRx 首席商務官<br/>(646) 335-5923<br/>mduffy@nrxpharma.com</td>
<td><strong><em>Brian Korb</em></strong><br/>管理合夥人，astr partners<br/>(917) 653-5122<br/>brian.korb@astrpartners.com</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTJOU00zTXpJNE1EWXdJekl3T0RReE1qST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTJOU00zTXpJNE1EWXdJekl3T0RReE1qST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png"/></p>

NRXP

<p>NRX Pharmaceuticals 宣佈通過股權轉換消除其 540 萬美元的債務，預計到 2025 年底實現無債務的資產負債表。這一戰略舉措為公司在 2026 年的加速增長奠定了基礎，屆時可能會有藥物批准和臨牀擴展。公司對 Anson Funds 在生物技術股票面臨挑戰時期的支持表示感謝</p>

<ul>
<li>Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisions</li>
<li>Company anticipates that Dec 31 balance sheet will reflect no outstanding convertible debt</li>
<li>Debt-free balance sheet sets the stage for accelerated growth in 2026 with potential drug approvals and clinic expansions</li>
</ul>
<div class="lb-trans"><ul>
<li>剩餘的 540 萬美元債務通過戰略性股權轉換為普通股償還，沒有附加的認股權證或調整條款</li>
<li>公司預計截至 12 月 31 日的資產負債表將不再反映任何未償還的可轉換債務</li>
<li>無債務的資產負債表為 2026 年的加速增長奠定了基礎，預計將有潛在的藥物批准和診所擴展</li>
</ul>
</div><p>WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2 million USD to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt. NRx believes that this milestone properly positions the company’s capital structure for accelerated growth with anticipated drug approvals and clinic expansions in the coming year.</p>
<div class="lb-trans"><p>特拉華州威爾明頓，2025 年 12 月 18 日（GLOBE NEWSWIRE）-- NRx Pharmaceuticals, Inc.（納斯達克：NRXP），一家臨牀階段生物製藥公司，今天宣佈已通過普通股的股權轉換向 Anson Funds, LLC 償還了剩餘的 540 萬美元資產負債表債務。此交易沒有附帶認股權證或其他重新定價機制。Anson 最初向公司借款 1620 萬美元，用於償還之前的貸款和公司運營費用。通過此次償還，公司預計在 2025 年日曆年結束時將實現無債務的資產負債表。NRx 認為這一里程碑為公司的資本結構適當定位，以便在未來一年實現加速增長，預計將有藥物批准和診所擴展。</p>
</div><p>“We thank Anson Funds for supporting our Company during a challenging period for biotechnology equities and for enabling us to advance our pharmaceutical and clinical programs toward potential 2026 approval and expansion in support of patients with suicidal depression and PTSD,” said Dr. Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and its subsidiary HOPE Therapeutics.</p>
<div class="lb-trans"><p>“我們感謝 Anson Funds 在生物技術股票面臨挑戰的時期對我們公司的支持，並使我們能夠推進我們的製藥和臨牀項目，以期在 2026 年獲得批准並擴展，以支持有自殺傾向的抑鬱症和創傷後應激障礙患者，” NRx Pharmaceuticals 及其子公司 HOPE Therapeutics 的董事長兼首席執行官 Jonathan Javitt 博士表示。</p>
</div><p><strong>About NRx Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 NRx Pharmaceuticals, Inc.</strong></p>
</div><p>NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently re-filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals, Inc.（www.nrxpharma.com）是一家臨牀階段生物製藥公司，開發基於其 NMDA 平台的治療藥物，針對中樞神經系統疾病，特別是自殺性抑鬱症、慢性疼痛和創傷後應激障礙。公司正在開發 NRX-100（無防腐劑的靜脈注射氯胺酮）和 NRX-101（口服 D-氨基酸/氟哌啶醇）。NRX-100 已獲得針對抑鬱症中自殺意念的快速通道認證，包括雙相抑鬱症。NRX-101 已獲得針對自殺性雙相抑鬱症的突破性療法認證。NRx 最近重新提交了簡化新藥申請（ANDA），並啓動了 NRX-100 的新藥申請，申請用於治療抑鬱症患者的自殺意念，包括雙相抑鬱症的國家優先券計劃。</p>
</div><p><strong>Notice Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的通知</strong></p>
</div><p>The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;intend,&#34; &#34;look forward,&#34; and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at <strong>http://www.sec.gov</strong>. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>此處包含的信息包括根據 1934 年證券交易法第 21E 條及 1933 年證券法第 27A 條的修訂版的前瞻性聲明。前瞻性聲明通常包括預測性質的陳述，依賴於或涉及未來事件或條件，幷包括諸如 “可能”、“將”、“應該”、“會”、“期望”、“計劃”、“相信”、“打算”、“期待” 等類似表達。這些陳述涉及未來事件或公司的未來財務表現，並涉及已知和未知的風險、不確定性及其他因素，這些因素可能導致公司的實際結果與這些前瞻性聲明所表達或暗示的任何未來結果、活動水平、表現或成就存在重大差異。公司已報告已實現的監管里程碑，但未預測任何未來監管決定的結果。您不應對前瞻性聲明過於依賴，因為它們涉及已知和未知的風險、不確定性及其他因素，這些因素在某些情況下超出了公司的控制範圍，並可能會對實際結果、活動水平、表現或成就產生重大影響。任何前瞻性聲明反映了公司對未來事件的當前看法，並受這些及其他風險的影響，包括與公司運營、運營結果、增長戰略及其他事項（包括流動性）相關的不確定性和假設。有關公司及可能影響前瞻性聲明實現的風險因素的更詳細信息已在公司最近的 10-K 表格年度報告及其他向證券交易委員會提交的文件中列出。投資者和證券持有人被敦促在 SEC 網站上免費閲讀這些文件，網址為 <strong>http://www.sec.gov</strong>。除非適用法律要求，否則公司不承擔公開更新或修訂這些前瞻性聲明的義務，或更新實際結果可能與這些前瞻性聲明中預期的結果存在重大差異的原因，無論是由於新信息、未來事件還是其他原因。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For further information:</strong></td>
<td></td>
</tr>
<tr>
<td><strong><em>Matthew Duffy</em></strong> Chief Business Officer, NRx<br/>(646) 335-5923<br/>mduffy@nrxpharma.com</td>
<td><strong><em>Brian Korb</em></strong><br/>Managing Partner, astr partners<br/>(917) 653-5122<br/>brian.korb@astrpartners.com</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>如需更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td><strong><em>Matthew Duffy</em></strong> NRx 首席商務官<br/>(646) 335-5923<br/>mduffy@nrxpharma.com</td>
<td><strong><em>Brian Korb</em></strong><br/>管理合夥人，astr partners<br/>(917) 653-5122<br/>brian.korb@astrpartners.com</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTJOU00zTXpJNE1EWXdJekl3T0RReE1qST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDI2NSM3MzI4MDYwIzIwODQxMjI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/MTliNDExNWUtMTVmMy00YzM0LWJmNGEtYzRiMTk5ZTNiMTVkLTEwOTU2OTMtMjAyNS0xMi0xOC1lbg==/tiny/NRx-Pharmaceuticals-Inc.png"/></p>

NRX Pharmaceuticals（納斯達克代碼：NRXP）宣佈通過股權轉換消除所有資產負債表上的債務 | NRXP 股票新聞